Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4CNS 4Other hematologic neoplasm 3Genitourinary 3Gastrointestinal 3Breast 3Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Dermatologic 1

Conditions

Melanoma 1

Interventions

Interferon-alpha 6Radiosurgery 4Dacarbazine 4encorafenib 3binimetinib 3aldesleukin 3Radiotherapy 3Methotrexate 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Etoposide 3Cyclophosphamide 3Cisplatin 3Watchful Waiting 2Vincristine 2Vinblastine 2Temozolomide 2Polymerase Chain Reaction 2Nivolumab 2Ipilimumab 2Introns 2Interferon alpha-2 2Immunologic Techniques 2Flow Cytometry 2Carboplatin 2trametinib 1tebentafusp 1sulforaphane 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Observation × Dermatologic × Clear all
NCT00003641 2026-02-25

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
1,150 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡